Literature DB >> 2465677

Experimental cerebral vasospasm: resolution by iloprost.

N Egemen1, K Birler, N Avman, R K Türker.   

Abstract

A new stable analogue of prostacyclin, iloprost, was tested on the basilar artery of anaesthetized rabbits constricted by electrical stimulation and intracisternal injection of autologous blood. The vasospasm induced by these stimuli was effectively relieved (about 100%) by topical application of iloprost, a stable analogue of prostacyclin (PGI2), and no constriction occurred on further stimulation within one hour. The mechanisms of the action of iloprost and its possible therapeutic value in subarachnoid haemorrhage are discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2465677     DOI： 10.1007/bf01790774

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN： 0001-6268            Impact factor:   2.216


  24 in total

1.  Experimental cerebral vasospasm in cats: modification by a new synthetic vasodilator YC-93.

Authors:  Y Handa; S Yoneda; T Koyama; M Matsuda; H Handa
Journal:  Surg Neurol       Date:  1975-04

2.  Prolonged vasospasm produced by the breakdown products of erythrocytes.

Authors:  K Osaka
Journal:  J Neurosurg       Date:  1977-09       Impact factor: 5.115

Review 3.  Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

4.  Effect of prostacyclin and adenosine triphosphate on vasospasm of canine basilar artery.

Authors:  S Haciyakupoğlu; M Kaya; E Cetinalp; A Yücesoy
Journal:  Surg Neurol       Date:  1985-08

5.  The role of the prostacyclin-thromboxane system in cerebral vasospasm following induced subarachnoid hemorrhage in the rabbit.

Authors:  R C Chan; F A Durity; G B Thompson; R A Nugent; M Kendall
Journal:  J Neurosurg       Date:  1984-12       Impact factor: 5.115

6.  Effect of phenoxybenzamine on experimental cerebral arterial spasm in cats.

Authors:  J Handa; S Yoneda; M Matsuda; T Koyama; H Handa
Journal:  Surg Neurol       Date:  1975-02

7.  Effects of intracerebroventricular administration of prostaglandins I2, E2, F2 alpha and indomethacin on blood pressure in the rat.

Authors:  K Kondo; T Okuno; T Saruta; E Kato
Journal:  Prostaglandins       Date:  1979-05

8.  Experimental cerebral vasospasm: resolution by chlorpromazine.

Authors:  O R Blaumanis; P A Grady
Journal:  Surg Neurol       Date:  1982-04

9.  Iloprost maintains acetylcholine relaxations of isolated rabbit aortic strips submitted to hypoxia.

Authors:  R K Türker; E Demirel
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

10.  Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581.

Authors:  T Sasaki; S Wakai; T Asano; K Takakura; K Sano
Journal:  J Neurosurg       Date:  1982-07       Impact factor: 5.115
View more
  4 in total

1.  Experimental basilar artery spasm caused by autologous blood application: effects of clot removal and topical nicardipine.

Authors:  R Tuncer
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

2.  Transclival approach to rabbit basilar artery for experimental induction of chronic vasospasm.

Authors:  N Egemen; U Sanlidilek; A Zorlutuna; M Başkaya; S Bilgiç; S Cağlar; A Unlü
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 3.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

4.  Efficacy of iloprost and montelukast combination on spinal cord ischemia/reperfusion injury in a rat model.

Authors:  Gokhan Lafci; Hikmet Selcuk Gedik; Kemal Korkmaz; Havva Erdem; Omer Faruk Cicek; Osman Arikan Nacar; Levent Yildirim; Ertugrul Kaya; Handan Ankarali
Journal:  J Cardiothorac Surg       Date:  2013-04-04       Impact factor: 1.637
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.